APIDRA (insulin glulisine rdna origin inj)
(insulin glulisine [rDNA origin]) Injection Solution for Injection
DRUG DESCRIPTION
APIDRA (insulin glulisine rdna origin inj) ® (insulin glulisine [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12). Insulin glulisine differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Chemically, insulin glulisine is 3B-lysine- 29B-glutamic acid-human insulin, has the empirical formula C258H384N64O78S6 and a molecular weight of 5823 and has the following structural formula:
APIDRA (insulin glulisine rdna origin inj) is a sterile, aqueous, clear, and colorless solution. Each milliliter of APIDRA (insulin glulisine rdna origin inj) contains 100 units (3.49 mg) insulin glulisine, 3.15 mg metacresol, 6 mg tromethamine, 5 mg sodium chloride, 0.01 mg polysorbate 20, and water for injection. APIDRA (insulin glulisine rdna origin inj) has a pH of approximately 7.3. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide.
INDICATIONS
APIDRA (insulin glulisine [rdna origin] inj) is indicated to improve glycemic control in adults and children with diabetes mellitus.
DOSAGE AND ADMINISTRATION
Dosage considerations
APIDRA (insulin glulisine [rdna origin] inj) is a recombinant insulin analog that is equipotent to human insulin (i.e. one unit of APIDRA (insulin glulisine [rdna origin] inj) has the same glucose-lowering effect as one unit of regular human insulin) when given intravenously. When given subcutaneously, APIDRA (insulin glulisine [rdna origin] inj) has a more rapid onset of action and a shorter duration of action than regular human insulin.
The dosage of APIDRA (insulin glulisine [rdna origin] inj) must be individualized. Blood glucose monitoring is essential in all patients receiving insulin therapy.
The total daily insulin requirement may vary and is usually between 0.5 to 1 Unit/kg/day. Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs.
Subcutaneous administration
APIDRA (insulin glulisine [rdna origin] inj) should be given within 15 minutes before a meal or within 20 minutes after starting a meal.
APIDRA (insulin glulisine [rdna origin] inj) given by subcutaneous injection should generally be used in regimens with an intermediate or long-acting insulin.
APIDRA (insulin glulisine [rdna origin] inj) should be administered by subcutaneous injection in the abdominal wall, thigh, or upper arm. Injection sites should be rotated within the same region (abdomen, thigh or upper arm) from one injection to the next to reduce the risk of lipodystrophy [See ADVERSE REACTIONS].
Continuous subcutaneous infusion (insulin pump)
APIDRA (insulin glulisine [rdna origin] inj) may be administered by continuous subcutaneous infusion in the abdominal wall. Do not use diluted or mixed insulins in external insulin pumps. Infusion sites should be rotated within the same region to reduce the risk of lipodystrophy [See ADVERSE REACTIONS]. The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen.
The following insulin pumps† have been used in APIDRA (insulin glulisine [rdna origin] inj) clinical trials conducted by sanofi-aventis, the manufacturer of APIDRA (insulin glulisine [rdna origin] inj) :
" Disetronic® H-Tron® plus V100 and D-Tron® with Disetronic catheters (Rapid™, Rapid C™, Rapid D™, and Tender™)
" MiniMed® Models 506, 507, 507c and 508 with MiniMed catheters (Sof-set Ultimate QR™, and Quick-set™).
Before using a different insulin pump with APIDRA (insulin glulisine [rdna origin] inj) , read the pump label to make sure the pump has been evaluated with APIDRA (insulin glulisine [rdna origin] inj) .
Physicians and patients should carefully evaluate information on pump use in the APIDRA (insulin glulisine [rdna origin] inj) prescribing information, Patient Information Leaflet, and the pump manufacturer's manual. APIDRA (insulin glulisine [rdna origin] inj) -specific information should be followed for in-use time, frequency of changing infusion sets, or other details specific to APIDRA (insulin glulisine [rdna origin] inj) usage, because APIDRA (insulin glulisine [rdna origin] inj) -specific information may differ from general pump manual instructions.
Based on in vitro studies which have shown loss of the preservative, metacresol and insulin degradation, APIDRA (insulin glulisine [rdna origin] inj) in the reservoir should be changed at least every 48 hours. APIDRA (insulin glulisine [rdna origin] inj) in clinical use should not be exposed to temperatures greater than 98.6° F (37° C). [See WARNINGS AND PRECAUTIONS and HOW SUPPLIED/Storage and Handling].
Intravenous administration
APIDRA (insulin glulisine [rdna origin] inj) can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and serum potassium to avoid hypoglycemia and hypokalemia. For intravenous use, APIDRA (insulin glulisine [rdna origin] inj) should be used at concentrations of 0.05 Units/mL to 1 Unit/mL insulin glulisine in infusion systems using polyvinyl chloride (PVC) bags. APIDRA (insulin glulisine [rdna origin] inj) has been shown to be stable only in normal saline solution (0.9% sodium chloride). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer insulin mixtures intravenously.
HOW SUPPLIED
Dosage Forms And Strengths
APIDRA (insulin glulisine [rdna origin] inj) 100 units per mL (U-100) is available as:
" 10 mL vials
" 3 mL cartridges for use in the OptiClik® Insulin Delivery Device
APIDRA (insulin glulisine [rdna origin] inj) 100 units per mL (U-100) is available as:
10 mL vials..........................NDC 0088-2500-33
3 mL cartridge system*, package of 5..................NDC 0088-2500-52
* Cartridge systems are for use only in OptiClik® (Insulin Delivery Device)
Storage
Do not use after the expiration date.
Unopened Vial/Cartridge System
Unopened APIDRA (insulin glulisine [rdna origin] inj) vials and cartridge systems should be stored in a refrigerator, 36°F-46°F (2°C-8°C). Protect from light. APIDRA (insulin glulisine [rdna origin] inj) should not be stored in the freezer and it should not be allowed to freeze. Discard if it has been frozen.
Unopened vials/cartridge systems not stored in a refrigerator must be used within 28 days.
Open (In-Use) Vial:
Opened vials, whether or not refrigerated, must be used within 28 days. If refrigeration is not possible, the open vial in use can be kept unrefrigerated for up to 28 days away from direct heat and light, as long as the temperature is not greater than 77°F (25°C).
Open (In-Use) Cartridge System
The opened (in-use) cartridge system inserted in OptiClik® should NOT be refrigerated but should be kept below 77°F (25°C) away from direct heat and light. The opened (in-use) cartridge system must be discarded after 28 days. Do not store OptiClik®, with or without cartridge system, in a refrigerator at any time.
Infusion sets
Infusion sets (reservoirs, tubing, and catheters) and the APIDRA (insulin glulisine [rdna origin] inj) in the reservoir should be discarded after 48 hours of use or after exposure to temperatures that exceed 98.6°F (37°C).
Intravenous use
Infusion bags prepared as indicated under DOSAGE AND ADMINISTRATION are stable at room temperature for 48 hours.
Preparation and Handling
After dilution for intravenous use, the solution should be inspected visually for particulate matter and discoloration prior to administration. Do not use the solution if it has become cloudy or contains particles; use only if it is clear and colorless. APIDRA (insulin glulisine [rdna origin] inj) is not compatible with Dextrose solution and Ringers solution and, therefore, cannot be used with these solution fluids. The use of APIDRA (insulin glulisine [rdna origin] inj) with other solutions has not been studied and is, therefore, not recommended.
Cartridge system: If OptiClik® (the Insulin Delivery Device for APIDRA (insulin glulisine [rdna origin] inj) ) malfunctions, APIDRA (insulin glulisine [rdna origin] inj) may be drawn from the cartridge system into a U-100 syringe and injected.
SIDE EFFECTS
The following adverse reactions are discussed elsewhere:
Hypoglycemia [See WARNINGS AND PRECAUTIONS]
Hypokalemia [See WARNINGS AND PRECAUTIONS]
Clinical trial experience
Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.
The frequencies of adverse drug reactions during APIDRA (insulin glulisine [rdna origin] inj) clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in the tables below.
Table 1: Treatment -emergent adverse events in pooled studies of adults with type 1 diabetes (adverse events with frequency ? 5%)
APIDRA, %
(n=950) All comparatorsa, %
(n=641)
Nasopharyngitis 10.6 12.9
Hypoglycemiab 6.8 6.7
Upper respiratory tract infection 6.6 5.6
Influenza 4.0 5.0
a Insulin lispro, regular human insulin, insulin aspart
b Only severe symptomatic hypoglycemia
Table 2: Treatment -emergent adverse events in pooled studies of adults with type 2 diabetes (adverse events with frequency ? 5%)
APIDRA, %
(n=883) Regular human insulin, %
(n=883)
Upper respiratory tract infection 10.5 7.7
Nasopharyngitis 7.6 8.2
Edema peripheral 7.5 7.8
Influenza 6.2 4.2
Arthralgia 5.9 6.3
Hypertension 3.9 5.3
" Pediatrics
Table 3 summarizes the adverse reactions occurring with frequency higher than 5% in a clinical study in children and adolescents with type 1 diabetes treated with APIDRA (insulin glulisine [rdna origin] inj) (n=277) or insulin lispro (n=295).
Table 3: Treatment -emergent adverse events in children and adolescents with type 1 diabetes (adverse reactions with frequency ≥5%)
APIDRA, %
(n=277) Lispro, %
(n=295)
Nasopharyngitis 9.0 9.5
Upper respiratory tract infection 8.3 10.8
Headache 6.9 11.2
Hypoglycemic seizure 6.1 4.7
" Severe symptomatic hypoglycemia
Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including APIDRA [See WARNINGS AND PRECAUTIONS]. The rates and incidence of severe symptomatic hypoglycemia, defined as hypoglycemia requiring intervention from a third party, were comparable for all treatment regimens (see Table 4). In the phase 3 clinical trial, children and adolescents with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia in the two treatment groups compared to adults with type 1 diabetes. (see Table 4) [See Clinical Studies].
Table 4: Severe Symptomatic Hypoglycemia*
" Insulin initiation and intensification of glucose control
Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.
" Lipodystrophy
Long-term use of insulin, including APIDRA (insulin glulisine [rdna origin] inj) , can cause lipodystrophy at the site of repeated insulin injections or infusion. Lipodystrophy includes lipohypertrophy (thickening of adipose tissue) and lipoatrophy (thinning of adipose tissue), and may affect insulin absorption. Rotate insulin injection or infusion sites within the same region to reduce the risk of lipodystrophy. [See DOSAGE AND ADMINISTRATION].
" Weight gain
Weight gain can occur with insulin therapy, including APIDRA (insulin glulisine [rdna origin] inj) , and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.
" Peripheral Edema
Insulin, including APIDRA (insulin glulisine [rdna origin] inj) , may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
" Adverse Reactions with Continuous Subcutaneous Insulin Infusion (CSII)
In a 12-week randomized study in patients with type 1 diabetes (n=59), the rates of catheter occlusions and infusion site reactions were similar for APIDRA (insulin glulisine [rdna origin] inj) and insulin aspart treated patients (Table 5).
Table 5: Catheter Occlusions and Infusion Site Reactions.
APIDRA
(n=29) insulin aspart
(n=30)
Catheter occlusions/month 0.08 0.15
Infusion site reactions 10.3% (3/29) 13.3% (4/30)
" Allergic Reactions
Local Allergy
As with any insulin therapy, patients taking APIDRA (insulin glulisine [rdna origin] inj) may experience redness, swelling, or itching at the site of injection. These minor reactions usually resolve in a few days to a few weeks, but in some occasions may require discontinuation of APIDRA (insulin glulisine [rdna origin] inj) . In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique.
Systemic Allergy
Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with any insulin, including APIDRA (insulin glulisine [rdna origin] inj) . Generalized allergy to insulin may cause whole body rash (including pruritus), dyspnea, wheezing, hypotension, tachycardia, or diaphoresis.
In controlled clinical trials up to 12 months duration, potential systemic allergic reactions were reported in 79 of 1833 patients (4.3%) who received APIDRA (insulin glulisine [rdna origin] inj) and 58 of 1524 patients (3.8%) who received the comparator short-acting insulins. During these trials treatment with APIDRA (insulin glulisine [rdna origin] inj) was permanently discontinued in 1 of 1833 patients due to a potential systemic allergic reaction.
Localized reactions and generalized myalgias have been reported with the use of metacresol, which is an excipient of APIDRA (insulin glulisine [rdna origin] inj) .
Antibody Production
In a study in patients with type 1 diabetes (n=333), the concentrations of insulin antibodies that react with both human insulin and insulin glulisine (cross-reactive insulin antibodies) remained near baseline during the first 6 months of the study in the patients treated with APIDRA (insulin glulisine [rdna origin] inj) . A decrease in antibody concentration was observed during the following 6 months of the study. In a study in patients with type 2 diabetes (n=411), a similar increase in cross-reactive insulin antibody concentration was observed in the patients treated with APIDRA (insulin glulisine [rdna origin] inj) and in the patients treated with human insulin during the first 9 months of the study. Thereafter the concentration of antibodies decreased in the APIDRA (insulin glulisine [rdna origin] inj) patients and remained stable in the human insulin patients. There was no correlation between cross-reactive insulin antibody concentration and changes in HbA1c, insulin doses, or incidence of hypoglycemia. The clinical significance of these antibodies is not known.
APIDRA (insulin glulisine [rdna origin] inj) did not elicit a significant antibody response in a study of children and adolescents with type 1 diabetes.
Postmarketing experience
The following adverse reactions have been identified during post-approval use of APIDRA (insulin glulisine [rdna origin] inj) . Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.
Medication errors have been reported in which other insulins, particularly long-acting insulins, have been accidentally administered instead of APIDRA [See Patient Counseling Information].
DRUG INTERACTIONS
A number of drugs affect glucose metabolism and may necessitate insulin dose adjustment and particularly close monitoring.
Drugs that may increase the blood glucose-lowering effect of insulins including APIDRA (insulin glulisine [rdna origin] inj) , and therefore increase the risk of hypoglycemia, include oral antidiabetic products, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates, somatostatin analogs, and sulfonamide antibiotics.
Drugs that may reduce the blood-glucose-lowering effect of APIDRA (insulin glulisine [rdna origin] inj) include corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), glucagon, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), protease inhibitors, and atypical antipsychotics.
Beta-blockers, clonidine, lithium salts, and alcohol may either increase or decrease the blood-glucose-lowering effect of insulin.
Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
The signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs such as beta-blockers, clonidine, guanethidine, and reserpine.
WARNINGS
Included as part of the PRECAUTIONS section.
PRECAUTIONS
Dosage adjustment and monitoring
Glucose monitoring is essential for patients receiving insulin therapy. Changes to an insulin regimen should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose. Concomitant oral antidiabetic treatment may need to be adjusted.
As with all insulin preparations, the time course of action for APIDRA (insulin glulisine [rdna origin] inj) may vary in different individuals or at different times in the same individual and is dependent on many conditions, including the site of injection, local blood supply, or local temperature. Patients who change their level of physical activity or meal plan may require adjustment of insulin dosages.
Hypoglycemia
Hypoglycemia is the most common adverse reaction of insulin therapy, including APIDRA (insulin glulisine [rdna origin] inj) . The risk of hypoglycemia increases with tighter glycemic control. Patients must be educated to recognize and manage hypoglycemia. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or death. Severe hypoglycemia requiring the assistance of another person and/or parenteral glucose infusion or glucagon administration has been observed in clinical trials with insulin, including trials with APIDRA (insulin glulisine [rdna origin] inj) .
The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of hypoglycemia [See DRUG INTERACTIONS].
As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.
Rapid changes in serum glucose levels may induce symptoms similar to hypoglycemia in persons with diabetes, regardless of the glucose value. Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as longstanding diabetes, diabetic nerve disease, use of medications such as beta-blockers [See DRUG INTERACTIONS], or intensified diabetes control. These situations may result in severe hypoglycemia (and, possibly, loss of consciousness) prior to the patient's awareness of hypoglycemia.
Intravenously administered insulin has a more rapid onset of action than subcutaneously administered insulin, requiring closer monitoring for hypoglycemia.
Hypersensitivity and allergic reactions
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including APIDRA [See ADVERSE REACTIONS].
Hypokalemia
All insulin products, including APIDRA (insulin glulisine [rdna origin] inj) , cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations). Monitor glucose and potassium frequently when APIDRA (insulin glulisine [rdna origin] inj) is administered intravenously.
Renal or hepatic impairment
Frequent glucose monitoring and insulin dose reduction may be required in patients with renal or hepatic impairment [See CLINICAL PHARMACOLOGY].
Mixing of insulins
APIDRA (insulin glulisine [rdna origin] inj) for subcutaneous injection should not be mixed with insulin preparations other than NPH insulin. If APIDRA (insulin glulisine [rdna origin] inj) is mixed with NPH insulin, APIDRA (insulin glulisine [rdna origin] inj) should be drawn into the syringe first. Injection should occur immediately after mixing.
Do not mix APIDRA (insulin glulisine [rdna origin] inj) with other insulins for intravenous administration or for use in a continuous subcutaneous infusion pump.
APIDRA (insulin glulisine [rdna origin] inj) for intravenous administration should not be diluted with solutions other than 0.9% sodium chloride (normal saline). The efficacy and safety of mixing APIDRA (insulin glulisine [rdna origin] inj) with diluents or other insulins for use in external subcutaneous infusion pumps have not been established.
Subcutaneous insulin infusion pumps
When used in an external insulin pump for subcutaneous infusion, APIDRA (insulin glulisine [rdna origin] inj) should not be diluted or mixed with any other insulin. APIDRA (insulin glulisine [rdna origin] inj) in the reservoir should be changed at least every 48 hours. APIDRA (insulin glulisine [rdna origin] inj) should not be exposed to temperatures greater than 98.6° F (37° C).
Malfunction of the insulin pump or infusion set or insulin degradation can rapidly lead to hyperglycemia and ketosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Interim subcutaneous injections with APIDRA (insulin glulisine [rdna origin] inj) may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. [See DOSAGE AND ADMINISTRATION, HOW SUPPLIED/Storage and Handling, and Patient Counseling Information].
Intravenous administration
When APIDRA (insulin glulisine [rdna origin] inj) is administered intravenously, glucose and potassium levels must be closely monitored to avoid potentially fatal hypoglycemia and hypokalemia.
Do not mix APIDRA (insulin glulisine [rdna origin] inj) with other insulins for intravenous administration. APIDRA (insulin glulisine [rdna origin] inj) may be diluted only in normal saline solution.
Drug interactions
Some medications may alter insulin requirements and the risk for hypoglycemia or hyperglycemia [See DRUG INTERACTIONS].
Nonclinical Toxicology
Carcinogenesis, mutagenesis, impairment of fertility
Standard 2-year carcinogenicity studies in animals have not been performed. In Sprague Dawley rats, a 12-month repeat dose toxicity study was conducted with insulin glulisine at subcutaneous doses of 2.5, 5, 20 or 50 Units/kg twice daily (dose resulting in an exposure 1, 2, 8, and 20 times the average human dose, based on body surface area comparison).
There was a non-dose dependent higher incidence of mammary gland tumors in female rats administered insulin glulisine compared to untreated controls. The incidence of mammary tumors for insulin glulisine and regular human insulin was similar. The relevance of these findings to humans is not known. Insulin glulisine was not mutagenic in the following tests: Ames test, in vitro mammalian chromosome aberration test in V79 Chinese hamster cells, and in vivo mammalian erythrocyte micronucleus test in rats.
In fertility studies in male and female rats at subcutaneous doses up to 10 Units/kg once daily (dose resulting in an exposure 2 times the average human dose, based on body surface area comparison), no clear adverse effects on male and female fertility, or general reproductive performance of animals were observed.
Use In Specific Populations
Pregnancy
Pregnancy Category C: Reproduction and teratology studies have been performed with insulin glulisine in rats and rabbits using regular human insulin as a comparator. Insulin glulisine was given to female rats throughout pregnancy at subcutaneous doses up to 10 U/kg once daily (dose resulting in an exposure 2 times the average human dose, based on body surface area comparison) and did not have any remarkable toxic effects on embryo-fetal development.
Insulin glulisine was given to female rabbits throughout pregnancy at subcutaneous doses up to 1.5 Units/kg/day (dose resulting in an exposure 0.5 times the average human dose, based on body surface area comparison). Adverse effects on embryo-fetal development were only seen at maternal toxic dose levels inducing hypoglycemia. Increased incidence of post-implantation losses and skeletal defects were observed at a dose level of 1.5 Units/kg once daily (dose resulting in an exposure 0.5 times the average human dose, based on body surface area comparison) that also caused mortality in dams. A slight increased incidence of post-implantation losses was seen at the next lower dose level of 0.5 Units/kg once daily (dose resulting in an exposure 0.2 times the average human dose, based on body surface area comparison) which was also associated with severe hypoglycemia but there were no defects at that dose. No effects were observed in rabbits at a dose of 0.25 Units/kg once daily (dose resulting in an exposure 0.1 times the average human dose, based on body surface area comparison). The effects of insulin glulisine did not differ from those observed with subcutaneous regular human insulin at the same doses and were attributed to secondary effects of maternal hypoglycemia.
There are no well-controlled clinical studies of the use of APIDRA (insulin glulisine [rdna origin] inj) in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is essential for patients with diabetes or a history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. Insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients.
Nursing mothers
It is unknown whether insulin glulisine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when APIDRA (insulin glulisine [rdna origin] inj) is administered to a nursing woman. Use of APIDRA (insulin glulisine [rdna origin] inj) is compatible with breastfeeding, but women with diabetes who are lactating may require adjustments of their insulin doses.
Pediatric use
The safety and effectiveness of subcutaneous injections of APIDRA (insulin glulisine [rdna origin] inj) have been established in pediatric patients (age 4 to 17 years) with type 1 diabetes [See Clinical Studies]. APIDRA (insulin glulisine [rdna origin] inj) has not been studied in pediatric patients with type 1 diabetes younger than 4 years of age and in pediatric patients with type 2 diabetes.
As in adults, the dosage of APIDRA (insulin glulisine [rdna origin] inj) must be individualized in pediatric patients based on metabolic needs and frequent monitoring of blood glucose.
Geriatric use
In clinical trials (n=2408), APIDRA (insulin glulisine [rdna origin] inj) was administered to 147 patients ? 65 years of age and 27 patients ? 75 years of age. The majority of this small subset of elderly patients had type 2 diabetes. The change in HbA1c values and hypoglycemia frequencies did not differ by age. Nevertheless, caution should be exercised when APIDRA (insulin glulisine [rdna origin] inj) is administered to geriatric patients.
OVERDOSE
Excess insulin may cause hypoglycemia and, particularly when given intravenously, hypokalemia. Mild episodes of hypoglycemia usually can be treated with oral glucose.
Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes of hypoglycemia with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.
CONTRAINDICATIONS
APIDRA (insulin glulisine [rdna origin] inj) is contraindicated:
" during episodes of hypoglycemia
" in patients who are hypersensitive to APIDRA (insulin glulisine [rdna origin] inj) or to any of its excipients When used in patients with known hypersensitivity to APIDRA (insulin glulisine [rdna origin] inj) or its excipients, patients may develop localized or generalized hypersensitivity reactions [See ADVERSE REACTIONS].
" CLINICAL PHARMACOLOGY
" Mechanism of action
" Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
" The glucose lowering activities of APIDRA (insulin glulisine [rdna origin] inj) and of regular human insulin are equipotent when administered by the intravenous route. After subcutaneous administration, the effect of APIDRA (insulin glulisine [rdna origin] inj) is more rapid in onset and of shorter duration compared to regular human insulin. [See Pharmacodynamics].
" Pharmacodynamics
" Studies in healthy volunteers and patients with diabetes demonstrated that APIDRA (insulin glulisine [rdna origin] inj) has a more rapid onset of action and a shorter duration of activity than regular human insulin when given subcutaneously.
" In a study in patients with type 1 diabetes (n= 20), the glucose-lowering profiles of APIDRA (insulin glulisine [rdna origin] inj) and regular human insulin were assessed at various times in relation to a standard meal at a dose of 0.15 Units/kg. (Figure 1.)
" The maximum blood glucose excursion (? GLUmax; baseline subtracted glucose concentration) for APIDRA (insulin glulisine [rdna origin] inj) injected 2 minutes before a meal was 65 mg/dL compared to 64 mg/dL for regular human insulin injected 30 minutes before a meal (see Figure 1A), and 84 mg/dL for regular human insulin injected 2 minutes before a meal (see Figure 1B). The maximum blood glucose excursion for APIDRA (insulin glulisine [rdna origin] inj) injected 15 minutes after the start of a meal was 85 mg/dL compared to 84 mg/dL for regular human insulin injected 2 minutes before a meal (see Figure 1C).
" Figure 1. Serial mean blood glucose collected up to 6 hours following a single dose of APIDRA (insulin glulisine [rdna origin] inj) and regular human insulin. APIDRA (insulin glulisine [rdna origin] inj) given 2 minutes (APIDRA (insulin glulisine [rdna origin] inj) - pre) before the start of a meal compared to regular human insulin given 30 minutes (Regular - 30 min) before start of the meal (Figure 1A) and compared to regular human insulin (Regular - pre) given 2 minutes before a meal (Figure 1B). APIDRA (insulin glulisine [rdna origin] inj) given 15 minutes (APIDRA (insulin glulisine [rdna origin] inj) - post) after start of a meal compared to regular human insulin (Regular - pre) given 2 minutes before a meal (Figure 1C). On the x-axis zero (0) is the start of a 15-minute meal.
"
Arrow ? indicates start of a 15-minute meal
" In a randomized, open-label, two-way crossover study, 16 healthy male subjects received an intravenous infusion of APIDRA (insulin glulisine [rdna origin] inj) or regular human insulin with saline diluent at a rate of 0.8 milliUnits/kg/min for two hours. Infusion of the same dose of APIDRA (insulin glulisine [rdna origin] inj) or regular human insulin produced equivalent glucose disposal at steady state.
" Pharmacokinetics
" Absorption and bioavailability
" Pharmacokinetic profiles in healthy volunteers and patients with diabetes (type 1 or type 2) demonstrated that absorption of insulin glulisine was faster than that of regular human insulin.
" In a study in patients with type 1 diabetes (n=20) after subcutaneous administration of 0.15 Units/kg, the median time to maximum concentration (Tmax) was 60 minutes (range 40 to 120 minutes) and the peak concentration (Cmax) was 83 microUnits/mL (range 40 to 131 microUnits/mL) for insulin glulisine compared to a median Tmax of 120 minutes (range 60 to 239 minutes) and a Cmax of 50 microUnits/mL (range 35 to 71 microUnits/mL) for regular human insulin. (Figure 2)
" Figure 2. Pharmacokinetic profiles of insulin glulisine and regular human insulin in patients with type 1 diabetes after a dose of 0.15 Units/kg.
" Insulin glulisine and regular human insulin were administered subcutaneously at a dose of 0.2 Units/kg in an euglycemic clamp study in patients with type 2 diabetes (n=24) and a body mass index (BMI) between 20 and 36 kg/m2. The median time to maximum concentration (Tmax) was 100 minutes (range 40 to 120 minutes) and the median peak concentration (Cmax) was 84 microUnits/mL (range 53 to 165 microUnits/mL) for insulin glulisine compared to a median Tmax of 240 minutes (range 80 to 360 minutes) and a median Cmax of 41 microUnits/mL (range 33 to 61 microUnits/mL) for regular human insulin. (Figure 3.)
" Figure 3. Pharmacokinetic profiles of insulin glulisine and regular human insulin in patients with type 2 diabetes after a subcutaneous dose of 0.2 Units/kg.
" When APIDRA (insulin glulisine [rdna origin] inj) was injected subcutaneously into different areas of the body, the time-concentration profiles were similar. The absolute bioavailability of insulin glulisine after subcutaneous administration is approximately 70%, regardless of injection area (abdomen 73%, deltoid 71%, thigh 68%).
" In a clinical study in healthy volunteers (n=32) the total insulin glulisine bioavailability was similar after subcutaneous injection of insulin glulisine and NPH insulin (premixed in the syringe) and following separate simultaneous subcutaneous injections. There was 27% attenuation of the maximum concentration (Cmax) of APIDRA (insulin glulisine [rdna origin] inj) after premixing; however, the time to maximum concentration (Tmax) was not affected. No data are available on mixing APIDRA (insulin glulisine [rdna origin] inj) with insulin preparations other than NPH insulin. [See Clinical Studies].
" Distribution and elimination
" The distribution and elimination of insulin glulisine and regular human insulin after intravenous administration are similar with volumes of distribution of 13 and 21 L and half-lives of 13 and 17 minutes, respectively. After subcutaneous administration, insulin glulisine is eliminated more rapidly than regular human insulin with an apparent half-life of 42 minutes compared to 86 minutes.
" Clinical pharmacology in specific populations
" Pediatric patients
" The pharmacokinetic and pharmacodynamic properties of APIDRA (insulin glulisine [rdna origin] inj) and regular human insulin were assessed in a study conducted in children 7 to 11 years old (n=10) and adolescents 12 to 16 years old (n=10) with type 1 diabetes. The relative differences in pharmacokinetics and pharmacodynamics between APIDRA (insulin glulisine [rdna origin] inj) and regular human insulin in these patients with type 1 diabetes were similar to those in healthy adult subjects and adults with type 1 diabetes.
" Race
" A study in 24 healthy Caucasians and Japanese subjects compared the pharmacokinetics and pharmacodynamics after subcutaneous injection of insulin glulisine, insulin lispro, and regular human insulin. With subcutaneous injection of insulin glulisine, Japanese subjects had a greater initial exposure (33%) for the ratio of AUC(0-1h) to AUC(0-clamp end) than Caucasians (21%) although the total exposures were similar. There were similar findings with insulin lispro and regular human insulin.
" Obesity
" Insulin glulisine and regular human insulin were administered subcutaneously at a dose of 0.3 Units/kg in a euglycemic clamp study in obese, non-diabetic subjects (n=18) with a body mass index (BMI) between 30 and 40 kg/m2. The median time to maximum concentration (Tmax) was 85 minutes (range 49 to 150 minutes) and the median peak concentration (Cmax) was 192 microUnits/mL (range 98 to 380 microUnits/mL) for insulin glulisine compared to a median Tmax of 150 minutes (range 90 to 240 minutes) and a median Cmax of 86 microUnits/mL (range 43 to 175 microUnits/mL) for regular human insulin.
" The more rapid onset of action and shorter duration of activity of APIDRA (insulin glulisine [rdna origin] inj) and insulin lispro compared to regular human insulin were maintained in an obese non-diabetic population (n= 18). (Figure 4.)
" Figure 4. Glucose infusion rates (GIR) in a euglycemic clamp study after subcutaneous injection of 0.3 Units/kg of APIDRA (insulin glulisine [rdna origin] inj) , insulin lispro or regular human insulin in an obese population.
" Renal impairment
" Studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. In a study performed in 24 non-diabetic subjects with normal renal function (ClCr > 80 mL/min), moderate renal impairment (30-50 mL/min) and severe renal impairment ( < 30 mL/min), the subjects with moderate and severe renal impairment had increased exposure to insulin glulisine by 29% to 40% and reduced clearance of insulin glulisine by 20% to 25% compared to subjects with normal renal function. [See WARNINGS AND PRECAUTIONS].
" Hepatic impairment
" The effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of APIDRA (insulin glulisine [rdna origin] inj) has not been studied. Some studies with human insulin have shown increased circulating levels of insulin in patients with liver failure. [See WARNINGS AND PRECAUTIONS].
" Gender
" The effect of gender on the pharmacokinetics and pharmacodynamics of APIDRA (insulin glulisine [rdna origin] inj) has not been studied.
" Pregnancy
" The effect of pregnancy on the pharmacokinetics and pharmacodynamics of APIDRA (insulin glulisine [rdna origin] inj) has not been studied.
" Smoking
" The effect of smoking on the pharmacokinetics and pharmacodynamics of APIDRA (insulin glulisine [rdna origin] inj) has not been studied.
" Clinical Studies
" The safety and efficacy of APIDRA (insulin glulisine [rdna origin] inj) was studied in adult patients with type 1 and type 2 diabetes (n =1833) and in children and adolescent patients (4 to 17 years) with type 1 diabetes (n=572). The primary efficacy parameter in these trials was glycemic control, assessed using glycated hemoglobin (GHb reported as HbA1c equivalent).
" Type 1 Diabetes-Adults
" A 26-week, randomized, open-label, active-controlled, non-inferiority study was conducted in patients with type 1 diabetes to assess the safety and efficacy of APIDRA (insulin glulisine [rdna origin] inj) (n= 339) compared to insulin lispro (n= 333) when administered subcutaneously within 15 minutes before a meal. Insulin glargine was administered once daily in the evening as the basal insulin. There was a 4-week run-in period with insulin lispro and insulin glargine prior to randomization. Most patients were Caucasian (97%). Fifty eight percent of the patients were men. The mean age was 39 years (range 18 to 74 years). Glycemic control, the number of daily short-acting insulin injections and the total daily doses of APIDRA (insulin glulisine [rdna origin] inj) and insulin lispro were similar in the two treatment groups (Table 6).
" Table 6: Type 1 Diabetes Mellitus-Adult
Treatment duration
Treatment in combination with: 26 weeks Insulin glargine
APIDRA Insulin Lispro
Glycated hemoglobin (GHb)* (%)
Number of patients 331 322
Baseline mean 7.6 7.6
Adjusted mean change from baseline -0.1 -0.1
Treatment difference: APIDRA - Insulin Lispro
95% CI for treatment difference 0.0
(-0.1; 0.1)
Basal insulin dose (Units/day)
Baseline mean 24 24
Adjusted mean change from baseline 0 2
Short-acting insulin dose (Units/day)
Baseline mean 30 31
Adjusted mean change from baseline -1 -1
Mean number of short-acting insulin injections per day 3 3
Body weight (kg)
Baseline mean 73.9 74.1
Mean change from baseline 0.6 0.3
*GHb reported as HbA1c equivalent
" Type 2 Diabetes-Adults
" A 26-week, randomized, open-label, active-controlled, non-inferiority study was conducted in insulin-treated patients with type 2 diabetes to assess the safety and efficacy of APIDRA (insulin glulisine [rdna origin] inj) (n= 435) given within 15 minutes before a meal compared to regular human insulin (n=441) administered 30 to 45 minutes prior to a meal. NPH human insulin was given twice a day as the basal insulin. All patients participated in a 4-week run-in period with regular human insulin and NPH human insulin. Eighty-five percent of patients were Caucasian and 11% were Black. The mean age was 58 years (range 26 to 84 years). The average body mass index (BMI) was 34.6 kg/m2. At randomization, 58% of the patients were taking an oral antidiabetic agent. These patients were instructed to continue use of their oral antidiabetic agent at the same dose throughout the trial. The majority of patients (79%) mixed their short-acting insulin with NPH human insulin immediately prior to injection. The reductions from baseline in GHb were similar between the 2 treatment groups (see Table 7). No differences between APIDRA (insulin glulisine [rdna origin] inj) and regular human insulin groups were seen in the number of daily short-acting insulin injections or basal or short-acting insulin doses. (See Table 7.)
" Table 7: Type 2 Diabetes Mellitus-Adult
Treatment duration
Treatment in combination with: 26 weeksNPH human insulin
APIDRA Regular Human Insulin
Glycated hemoglobin (GHb)* (%)
Number of patients 404 403
Baseline mean 7.6 7.5
Adjusted mean change from baseline -0.5 -0.3
Treatment difference: APIDRA - Regular Human Insulin
95% CI for treatment difference -0.2
(-0.3; -0.1)
Basal insulin dose (Units/day)
Baseline mean 59 57
Adjusted mean change from baseline 6 6
Short-acting insulin dose (Units/day)
Baseline mean 32 31
Adjusted mean change from baseline 4 5
Mean number of short-acting insulin injections per day 2 2
Body weight (kg)
Baseline mean 100.5 99.2
Mean change from baseline 1.8 2.0
*GHb reported as HbA1c equivalent
" Type 1 Diabetes-Adults: Pre- and post-meal administration
" A 12-week, randomized, open-label, active-controlled, non-inferiority study was conducted in patients with type 1 diabetes to assess the safety and efficacy of APIDRA (insulin glulisine [rdna origin] inj) administered at different times with respect to a meal. APIDRA (insulin glulisine [rdna origin] inj) was administered subcutaneously either within 15 minutes before a meal (n=286) or immediately after a meal (n=296) and regular human insulin (n= 278) was administered subcutaneously 30 to 45 minutes prior to a meal. Insulin glargine was administered once daily at bedtime as the basal insulin. There was a 4-week run-in period with regular human insulin and insulin glargine followed by randomization. Most patients were Caucasian (94%). The mean age was 40 years (range 18 to 73 years). Glycemic control (see Table 8) was comparable for the 3 treatment regimens. No changes from baseline between the treatments were seen in the total daily number of short-acting insulin injections. (See Table 8.)
" Table 8: Pre- and Post-Meal Administration in Type 1 Diabetes Mellitus-Adult
Treatment duration
Treatment in combination with: 12 weeks
insulin glargine
APIDRA (insulin glulisine [rdna origin] inj)
pre meal 12 weeks
insulin glargine
APIDRA (insulin glulisine [rdna origin] inj)
post meal 12 weeks
insulin glargine
Regular Human
Insulin
Glycated hemoglobin (GHb)* (%)
Number of patients 268 276 257
Baseline mean 7.7 7.7 7.6
Adjusted mean change from baseline** -0.3 -0.1 -0.1
Basal insulin dose (Units/day)
Baseline mean 29 29 28
Adjusted mean change from baseline 1 0 1
Short-acting insulin dose (Units/day)
Baseline mean 29 29 27
Adjusted mean change from baseline -1 -1 2
Mean number of short-acting insulin injections per day 3 3 3
Body weight (kg)
Baseline mean 79.2 80.3 78.9
Mean change from baseline 0.3 -0.3 0.3
*GHb reported as HbA1c equivalent
**Adjusted mean change from baseline treatment difference (98.33% CI for treatment difference):
APIDRA (insulin glulisine [rdna origin] inj) pre meal vs. Regular Human Insulin - 0.1 (-0.3; 0.0)
APIDRA (insulin glulisine [rdna origin] inj) post meal vs. Regular Human Insulin 0.0 (-0.1; 0.2)
APIDRA (insulin glulisine [rdna origin] inj) post meal vs. pre meal 0.2 (0.0; 0.3)
" Type 1 Diabetes-Pediatric patients
" A 26-week, randomized, open-label, active-controlled, non-inferiority study was conducted in children and adolescents older than 4 years of age with type 1 diabetes mellitus to assess the safety and efficacy of APIDRA (insulin glulisine [rdna origin] inj) (n= 277) compared to insulin lispro (n= 295) when administered subcutaneously within 15 minutes before a meal. Patients also received insulin glargine (administered once daily in the evening) or NPH insulin (administered once in the morning and once in the evening). There was a 4-week run-in period with insulin lispro and insulin glargine or NPH prior to randomization. Most patients were Caucasian (91%). Fifty percent of the patients were male. The mean age was 12.5 years (range 4 to 17 years). Mean BMI was 20.6 kg/m2. Glycemic control (see Table 9) was comparable for the two treatment regimens.
" Table 9: Results from a 26-week study in pediatric patients with type 1 diabetes mellitus
Number of patients
Basal Insulin APIDRA (insulin glulisine [rdna origin] inj)
271
NPH or insulin glargine Lispro
291
NPH or insulin glargine
Glycated hemoglobin (GHb)* (%)
Baseline mean 8.2 8.2
Adjusted mean change from Baseline 0.1 0.2
Treatment Difference: Mean (95% confidence interval) -0.1(-0.2, 0.1)
Basal insulin dose (Units/kg/day)
Baseline mean 0.5 0.5
Mean change from baseline 0.0 0.0
Short-acting insulin dose (Units/kg/day)
Baseline mean 0.5 0.5
Mean change from baseline 0.0 0.0
Mean number of short-acting insulin injections per day 3 3
Baseline mean body weight (kg) 51.5 50.8
Mean weight change from baseline (kg) 2.2 2.2
*GHb reported as HbA1c equivalent
" Type 1 Diabetes-Adults: Continuous subcutaneous insulin infusion
" A 12-week randomized, active control study (APIDRA (insulin glulisine [rdna origin] inj) versus insulin aspart) conducted in adults with type 1 diabetes (APIDRA (insulin glulisine [rdna origin] inj) n= 29, insulin aspart n=30) evaluated the use of APIDRA (insulin glulisine [rdna origin] inj) in an external continuous subcutaneous insulin pump. All patients were Caucasian. The mean age was 46 years (range 21 to 73 years). The mean GHb increased from baseline to endpoint in both treatment groups (from 6.8% to 7.0% for APIDRA (insulin glulisine [rdna origin] inj) ; from 7.1% to 7.2% for insulin aspart).